Core Viewpoint - The announcement highlights that Zhejiang Daer Biotechnology, a subsidiary of Huadong Medicine, has received FDA approval for the clinical trial application of the drug DR10624, aimed at treating Metabolic Associated Steatotic Liver Disease (MASLD) [1] Group 1 - The drug DR10624 is a globally innovative long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, developed independently by Daer Biotechnology [1] - DR10624 has successfully completed Phase II clinical trials for severe hypertriglyceridemia, achieving positive top-line results [1] - The approval for the clinical trial will not have a significant impact on the company's recent performance [1]

Core Insights - The article discusses the rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), which now affects one-third of adults globally, emphasizing the importance of lifestyle interventions like diet and exercise in its management [6][9]. - A recent randomized controlled trial presented at the AASLD 2025 conference indicates that time-restricted eating (TRE) may significantly improve liver fat degeneration in overweight or obese MASLD patients, showing a reduction of 25.8% compared to a 0.7% increase in the standard intervention group [7][9]. Summary by Sections Prevalence and Management of MASLD - MASLD is becoming a major chronic liver disease affecting a significant portion of the adult population worldwide, necessitating effective management strategies [6]. - Lifestyle interventions, particularly dietary management, are highlighted as core components in the comprehensive management of MASLD [6]. Research Findings on Time-Restricted Eating - A 16-week randomized controlled trial included 337 overweight or obese MASLD patients, divided into three groups: standard intervention, calorie restriction, and time-restricted eating [9]. - The primary endpoint was the improvement of liver fat degeneration assessed by MRI-PDFF, with TRE showing a significant reduction in liver fat compared to the standard intervention group [9]. - TRE also demonstrated comparable effects to calorie restriction in terms of weight, waist circumference, and body fat improvements, while no significant differences were observed in liver stiffness, glucose homeostasis, or sleep quality among the groups [9].